A study to investigate the efficacy and safety of TRIV-573 compared with placebo in participants with moderate to severe atopic dermatitis
Key facts
- Where
- Katowice, Kielce, Lublin, Mikolow, Nowa Sol, Poznan, Szczecin, Warsaw és Wroclaw, LengyelországSee the 10 sites
- Phase
- 2. fázis
Where in Lengyelország
- Gyncentrum Sp. z o.o.Katowice, LengyelországToborzás még nem indult
- Provita Sp z o oKatowice, LengyelországToborzás még nem indult
- Zdybski Med Sp. z o.o.Kielce, LengyelországToborzás még nem indult
- Clinical Best Solutions Sp. z o.o., Sp. K.Lublin, LengyelországToborzás még nem indult
- St-Inspire Sp. z o.o.Mikolow, LengyelországToborzás még nem indult
- Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o.Nowa Sol, LengyelországToborzás még nem indult
- Twoja Przychodnia Poznanskie Centrum Medyczne Sp. z o.o.Poznan, LengyelországToborzás még nem indult
- Laser Clinic S.C. dr Tomasz Kochanowski dr Andrzej KrólickiSzczecin, LengyelországToborzás még nem indult
- Medicover Integrated Clinical Services Sp. z o.o.Warsaw, LengyelországToborzás még nem indult
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, LengyelországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Triveni Bio Inc.
- Trial code
- EU 2026-526485-25-00
- Record updated
- 2026. október 21.
- Original description
To assess the efficacy of TRIV-573 administered by SC injection in participants with moderate to severe atopic dermatitisRead full original descriptionShow less
A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants with Moderate to Severe Atopic Dermatitis
To assess the efficacy of TRIV-573 administered by SC injection in participants with moderate to severe atopic dermatitis
Inclusion: Aged 18 to 75 years, inclusive, with a diagnosis of moderate to severe, active, chronic, and symptomatic atopic dermatitis; Body weight ≥40 kg (88.2 pounds) at Screening; Willing to follow study instructions and avoid certain other medications during the study; No significant recent flares in atopic dermatitis.
Exclusion: Currently receiving a nonbiological investigational product or device; Severe or uncontrolled medical conditions; Known chronic liver disease.